- Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study
-
Kang YW, Baek YH, Lee SW, Park SJ, Yoon JS, Yoon KT, Hong Y, Heo NY, Seo KI, Lee SS, Cho HC, Shin JW
- KMID: 2516253
- J Korean Med Sci.
- 2021 May;36(21):e142.
- doi: 10.3346/jkms.2021.36.e142
Background: The advancement of treatment with direct-acting antiviral (DAA) agents has improved the cure rate of hepatitis C virus (HCV) infection close to 100%. The aim of our study was... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
-
Kwan BS, Kim JH, Park SJ, Choe WH, Kwon SY, Yoo BC
- KMID: 2513740
- Korean J Intern Med.
- 2021 Mar;36(2):292-304.
- doi: 10.3904/kjim.2019.297
Background/Aims: Chronic hepatitis C (CHC) treatment has dramatically improved since direct-acting antiviral (DAA) therapy was introduced. However, the use of DAA therapy in CHC patients with hepatocellular carcinoma (HCC) remains... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases
-
Tamaki N, Kurosaki M, Loomba R, Izumi N
- KMID: 2512730
- Ann Lab Med.
- 2021 Jan;41(1):16-24.
- doi: 10.3343/alm.2021.41.1.16
An accurate evaluation of liver fibrosis is clinically important in chronic liver diseases. Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel serum marker for liver fibrosis. In this review,... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study
-
Jeong JY, Jun DW, Park SJ, Sohn JH, Kim SG, Lee SW, Jeong SW, Kim MY, Kim W, Shim JJ, Kim HS, Suk KT, Ahn SB
- KMID: 2505588
- Korean J Intern Med.
- 2020 Sep;35(5):1074-1083.
- doi: 10.3904/kjim.2018.273
Background/Aims: We aimed to assess the role of vitamin D supplementation in the response to pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV) treatment in patients with chronic hepatitis C (CHC). Methods: Our... -
- CITED
-
- Close
- SHARE
-
- Close
- Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
-
Na SK, Song BC
- KMID: 2459785
- Clin Mol Hepatol.
- 2019 Sep;25(3):234-244.
- doi: 10.3350/cmh.2018.0108
Hepatitis C virus (HCV) infection is a major risk factor for liver cirrhosis and hepatocellular carcinoma (HCC), and is a leading cause of liver-related deaths worldwide. Recently available direct-acting antiviral... -
- CITED
-
- Close
- SHARE
-
- Close
- Prediction and Staging of Hepatic Fibrosis in Children with Hepatitis C Virus: A Machine Learning Approach
-
Barakat NH, Barakat SH, Ahmed N
- KMID: 2457469
- Healthc Inform Res.
- 2019 Jul;25(3):173-181.
- doi: 10.4258/hir.2019.25.3.173
OBJECTIVES: The aim of this study is to develop an intelligent diagnostic system utilizing machine learning for data cleansing, then build an intelligent model and obtain new cutoff values for... -
- CITED
-
- Close
- SHARE
-
- Close
- Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
-
Huang CF, Yu ML
- KMID: 2451919
- Clin Mol Hepatol.
- 2019 Jun;25(2):168-171.
- doi: 10.3350/cmh.2018.1014
During the clinical trial development of directly acting antivirals (DAAs), evidence regarding the treatment efficacy in chronic hepatitis C patients with hepatocellular carcinoma (HCC) was scarce because these patients have... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection
-
Sato S, Moriya K, Furukawa M, Saikawa S, Namisaki T, Kitade M, Kawaratani H, Kaji K, Takaya H, Shimozato , Sawada Y, Seki K, Kitagawa K, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H
- KMID: 2447252
- Clin Mol Hepatol.
- 2019 Mar;25(1):65-73.
- doi: 10.3350/cmh.2018.0070
BACKGROUND/AIMS: L-carnitine not only alleviates hyperammonemia and reduces muscle cramps in patients with liver cirrhosis, but also improves anemia in patients with chronic hepatitis and renal dysfunction. This study prospectively... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
-
Lee BS, Song MJ, Kwon JH, Lee TH, Jang JW, Kim SH, Lee SH, Kim HS, Kim JH, Kim SB, Ko SY, Song DS
- KMID: 2446804
- Gut Liver.
- 2019 Mar;13(2):191-196.
- doi: 10.5009/gnl18240
BACKGROUND/AIMS: We evaluated the efficacy and safety of daclatasvir (DCV) and asunaprevir (ASV) in patients with chronic hepatitis C virus (HCV) infection on hemodialysis. METHODS: We performed a single-arm, multicenter prospective... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
-
Ko SY, Choe WH
- KMID: 2433297
- Clin Mol Hepatol.
- 2018 Dec;24(4):351-357.
- doi: 10.3350/cmh.2017.0063
The advent of novel, direct-acting antiviral (DAA) regimens for hepatitis C virus (HCV) infection has revolutionized its treatment by producing a sustained virologic response of more than 95% with few... -
- CITED
-
- Close
- SHARE
-
- Close
- Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
-
Yeon JE
- KMID: 2428755
- Clin Mol Hepatol.
- 2018 Sep;24(3):294-296.
- doi: 10.3350/cmh.2018.1009
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
-
The Korean Association for the Study of the Liver (KASL)
- KMID: 2428752
- Clin Mol Hepatol.
- 2018 Sep;24(3):169-229.
- doi: 10.3350/cmh.2018.1004
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Use of sofosbuvir in chronic kidney disease: Is it necessary?
-
Lim TS, Ahn SH
- KMID: 2406037
- Clin Mol Hepatol.
- 2017 Dec;23(4):308-310.
- doi: 10.3350/cmh.2017.0109
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Quality of Life of Chronic Hepatitis C Patients and Its Associated Factors
-
Cho HJ, Park E
- KMID: 2385158
- Osong Public Health Res Perspect.
- 2017 Apr;8(2):124-129.
- doi: 10.24171/j.phrp.2017.8.2.04
OBJECTIVES: This study aimed to investigate the factors affecting the health-related quality of life (HRQOL) of patients with chronic hepatitis C (CHC). METHODS: This study is based on a descriptive survey... -
- CITED
-
- Close
- SHARE
-
- Close
- Illness Experience of Patients with Chronic Hepatitis C Participating in Clinical Trials
-
Cho HJ, Park E
- KMID: 2518300
- Osong Public Health Res Perspect.
- 2016 Dec;7(6):394-399.
- doi: 10.1016/j.phrp.2016.11.001
Objectives To understand the illness experience of patients with chronic hepatitis C participating in clinical trials in the sociocultural context of Korea in an in-depth and comprehensive manner. Methods A focused ethnography approach... -
- CITED
-
- Close
- SHARE
-
- Close
- Chronic hepatitis C healed by peginterferon-α and rivabirin treatment after kidney transplantation
-
Seok MG, Lee TH, Yun SR, Hwang WM, Yoon SH, Choe IS, Kang SJ, Hong JY, Kim DS
- KMID: 2366130
- Yeungnam Univ J Med.
- 2016 Dec;33(2):150-154.
- doi: 10.12701/yujm.2016.33.2.150
Hepatitis C virus (HCV) infection is present in a high proportion of patients with kidney transplantation. Compared with uninfected kidney transplant recipients, HCV infected kidney recipient have higher prevalence of... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Model for Predicting Hepatocellular Carcinomas in Patients with Post-Sustained Virologic Responses of Chronic Hepatitis C: A Case Control Study
-
Zeng QL, Li B, Zhang XX, Chen Y, Fu YL, Lv J, Liu YM, Yu ZJ
- KMID: 2412102
- Gut Liver.
- 2016 Nov;10(6):955-961.
- doi: 10.5009/gnl15321
BACKGROUND/AIMS: No clinical model exists to predict the occurrence of hepatocellular carcinoma in sustained virologic response-achieving (HCC after SVR) patients with chronic hepatitis C (CHC). METHODS: We performed a case-control study... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C
-
Kim MN, Kim HS, Kim JK, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han KH
- KMID: 2468276
- J Korean Med Sci.
- 2016 Sep;31(9):1431-1437.
- doi: 10.3346/jkms.2016.31.9.1431
Hepatitis C virus core antigen (HCV Ag) is a recently developed marker of hepatitis C virus (HCV) infection. We investigated the clinical utility of the new HCV Ag assay for... -
- CITED
-
- Close
- SHARE
-
- Close
- Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3
-
Jung YK
- KMID: 2373412
- Korean J Gastroenterol.
- 2016 Mar;67(3):132-136.
- doi: 10.4166/kjg.2016.67.3.132
Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have... -
- CITED
-
- Close
- SHARE
-
- Close
- Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1
-
Park SH
- KMID: 2373411
- Korean J Gastroenterol.
- 2016 Mar;67(3):127-131.
- doi: 10.4166/kjg.2016.67.3.127
The introduction of direct-acting antiviral agents (DAAs) has markedly improved the sustained virological response (SVR) rates in patients with chronic hepatitis C. Currently, four classes of DAAs targeting three HCV... -
- CITED
-
- Close
- SHARE
-
- Close
